Vir Biotechnology Inc (VIR)

$7.63

Live

Performance

  • $7.60
    $7.73
    $7.63
    downward going graph

    0.46%

    Downside

    Day's Volatility :1.75%

    Upside

    1.29%

    downward going graph
  • $7.12
    $13.09
    $7.63
    downward going graph

    6.68%

    Downside

    52 Weeks Volatility :45.61%

    Upside

    41.71%

    downward going graph

Returns

PeriodVir Biotechnology IncSector (Health Care)Index (Russel 2000)
3 Months
-24.83%
3.6%
0.0%
6 Months
-5.8%
10.2%
0.0%
1 Year
-6.61%
19.6%
0.0%
3 Years
-80.89%
16.8%
-23.0%

Highlights

Market Capitalization
1.1B
Book Value
$10.50
Earnings Per Share (EPS)
-3.58
Wall Street Target Price
33.86
Profit Margin
0.0%
Operating Margin TTM
-4304.23%
Return On Assets TTM
-16.55%
Return On Equity TTM
-29.78%
Revenue TTM
78.9M
Revenue Per Share TTM
0.58
Quarterly Revenue Growth YOY
-19.0%
Gross Profit TTM
1.0B
EBITDA
-500.2M
Diluted Eps TTM
-3.58
Quarterly Earnings Growth YOY
0.59
EPS Estimate Current Year
-3.39
EPS Estimate Next Year
-3.77
EPS Estimate Current Quarter
-0.89
EPS Estimate Next Quarter
-1.01

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Vir Biotechnology Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 343.77%

Current $7.63
Target $33.86

Company Financials

FY18Y/Y Change
Revenue
868.0K
↑ 482.55%
Net Income
-115.9M
↑ 65.9%
Net Profit Margin
-13.4K%
↑ 33529.85%
FY19Y/Y Change
Revenue
711.0K
↓ 18.09%
Net Income
-174.7M
↑ 50.74%
Net Profit Margin
-24.6K%
↓ 11217.95%
FY20Y/Y Change
Revenue
76.4M
↑ 10640.93%
Net Income
-298.7M
↑ 70.98%
Net Profit Margin
-391.09%
↑ 24177.55%
FY21Y/Y Change
Revenue
1.1B
↑ 1323.46%
Net Income
528.6M
↓ 276.98%
Net Profit Margin
48.62%
↑ 439.71%
FY22Y/Y Change
Revenue
1.6B
↑ 45.39%
Net Income
515.8M
↓ 2.41%
Net Profit Margin
32.64%
↓ 15.98%
FY23Y/Y Change
Revenue
86.2M
↓ 94.55%
Net Income
-615.1M
↓ 219.24%
Net Profit Margin
-713.69%
↓ 746.33%
Q1 FY23Q/Q Change
Revenue
46.7M
↑ 114.38%
Net Income
-141.0M
↑ 38.73%
Net Profit Margin
-301.76%
↑ 164.54%
Q2 FY23Q/Q Change
Revenue
-12.7M
↓ 127.23%
Net Income
-194.8M
↑ 38.18%
Net Profit Margin
1.5K%
↑ 1832.77%
Q3 FY23Q/Q Change
Revenue
-4.1M
↓ 67.79%
Net Income
-163.4M
↓ 16.1%
Net Profit Margin
4.0K%
↑ 2456.62%
Q4 FY23Q/Q Change
Revenue
16.8M
↓ 509.64%
Net Income
-116.0M
↓ 29.03%
Net Profit Margin
-690.85%
↓ 4678.48%
Q1 FY24Q/Q Change
Revenue
56.4M
↑ 235.83%
Net Income
-65.3M
↓ 43.71%
Net Profit Margin
-115.79%
↑ 575.06%
Q2 FY24Q/Q Change
Revenue
3.1M
↓ 94.55%
Net Income
-138.4M
↑ 111.99%
Net Profit Margin
-4.5K%
↓ 4384.31%
FY18Y/Y Change
Total Assets
191.6M
↓ 23.84%
Total Liabilities
370.8M
↑ 15.69%
FY19Y/Y Change
Total Assets
512.1M
↑ 167.27%
Total Liabilities
88.1M
↓ 76.23%
FY20Y/Y Change
Total Assets
918.8M
↑ 79.42%
Total Liabilities
201.9M
↑ 129.11%
FY21Y/Y Change
Total Assets
2.0B
↑ 112.71%
Total Liabilities
522.4M
↑ 158.74%
FY22Y/Y Change
Total Assets
2.8B
↑ 43.38%
Total Liabilities
724.1M
↑ 38.61%
FY23Y/Y Change
Total Assets
2.0B
↓ 30.05%
Total Liabilities
369.9M
↓ 48.92%
Q1 FY23Q/Q Change
Total Assets
2.7B
↓ 4.86%
Total Liabilities
695.1M
↓ 4.0%
Q2 FY23Q/Q Change
Total Assets
2.2B
↓ 15.83%
Total Liabilities
433.7M
↓ 37.61%
Q3 FY23Q/Q Change
Total Assets
2.0B
↓ 8.87%
Total Liabilities
369.8M
↓ 14.72%
Q4 FY23Q/Q Change
Total Assets
2.0B
↓ 4.15%
Total Liabilities
369.9M
↑ 0.01%
Q1 FY24Q/Q Change
Total Assets
1.8B
↓ 8.48%
Total Liabilities
246.6M
↓ 33.32%
Q2 FY24Q/Q Change
Total Assets
1.7B
↓ 6.94%
Total Liabilities
235.9M
↓ 4.35%
FY18Y/Y Change
Operating Cash Flow
-94.1M
↑ 41.75%
Investing Cash Flow
-60.4M
↑ 101.51%
Financing Cash Flow
25.0M
↓ 90.79%
FY19Y/Y Change
Operating Cash Flow
-129.6M
↑ 37.77%
Investing Cash Flow
-256.2M
↑ 323.81%
Financing Cash Flow
449.2M
↑ 1698.56%
FY20Y/Y Change
Operating Cash Flow
-190.9M
↑ 47.29%
Investing Cash Flow
-9.9M
↓ 96.15%
Financing Cash Flow
529.5M
↑ 17.86%
FY21Y/Y Change
Operating Cash Flow
-47.6M
↓ 75.08%
Investing Cash Flow
-140.8M
↑ 1327.84%
Financing Cash Flow
100.3M
↓ 81.05%
FY22Y/Y Change
Operating Cash Flow
1.7B
↓ 3595.04%
Investing Cash Flow
-1.2B
↑ 747.54%
Financing Cash Flow
34.8M
↓ 65.35%
Q1 FY23Q/Q Change
Operating Cash Flow
-125.8M
↓ 458.09%
Investing Cash Flow
98.1M
↓ 164.05%
Financing Cash Flow
2.3M
↑ 16.56%
Q2 FY23Q/Q Change
Operating Cash Flow
-389.2M
↑ 209.46%
Investing Cash Flow
230.3M
↑ 134.83%
Financing Cash Flow
3.2M
↑ 35.62%

Technicals Summary

Sell

Neutral

Buy

Vir Biotechnology Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vir Biotechnology Inc
Vir Biotechnology Inc
0.39%
-5.8%
-6.61%
-80.89%
-47.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vir Biotechnology Inc
Vir Biotechnology Inc
6.4
NA
NA
-3.39
-0.3
-0.17
NA
10.5
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vir Biotechnology Inc
Vir Biotechnology Inc
Buy
$1.1B
-47.05%
6.4
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Vir Biotechnology Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 56.37M → 3.07M (in $), with an average decrease of 94.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -65.27M → -138.37M (in $), with an average decrease of 112.0% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 92.6%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 125.7%

Institutional Holdings

  • SB INVESTMENT ADVISERS (UK) LTD

    12.21%

  • BlackRock Inc

    12.03%

  • Vanguard Group Inc

    9.40%

  • State Street Corp

    3.73%

  • Baillie Gifford & Co Limited.

    2.87%

  • Orbimed Advisors, LLC

    1.70%

Company Information

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Organization
Vir Biotechnology Inc
Employees
587
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Industry
Commercial Services

Discover More

FAQs